1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,630 | 5,890 | 20.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 2 | HKEx | ||
| 28.02. | Biocytogen verkündet klinischen Meilenstein: Erster Patient in Phase-1-Studie von IDEAYAs erstklassigem B7H3/PTK7-bispezifischen TOP1-ADC IDE034 behandelt | 538 | Business Wire | IDE034 ist ein B7H3/PTK7-bispezifisches TOP1 ADC, das darauf ausgelegt ist, Tumorzellen, die sowohl B7H3 als auch PTK7 exprimieren, bevorzugt anzugreifen. Es wird derzeit sowohl als Monotherapie... ► Artikel lesen | |
| 26.02. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR 2025 | 1 | HKEx | ||
| 12.02. | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 12.02. | BIOCYTOGEN-B (02315): (1) POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 12, 2026; (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR; ... | - | HKEx | ||
| 29.01. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT OF ESTIMATED ANNUAL RESULTS FOR THE YEAR 2025 | 3 | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 26.01. | BIOCYTOGEN-B (02315): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 4 | HKEx | ||
| 12.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT EXPANDED COLLABORATION WITH ACEPODIA THROUGH OPTION-BASED EVALUATION FRAMEWORK FOR FIRST-IN-CLASS DUAL-PAYLOAD ... | 1 | HKEx | ||
| 09.01. | Biocytogen und Acepodia erweitern Kooperation durch optionsbasiertes Evaluierungsmodell für bispezifische und Dual-Payload-First-in-Class-ADC (BsAD2C) | 484 | Business Wire | Die erweiterte Zusammenarbeit knüpft an die jüngsten gemeinsamen Entwicklungsanstrengungen von Acepodia und Biocytogen zur Evaluierung ausgewählter bispezifischer Antikörper- und Dual-Payload-ADC-Programme... ► Artikel lesen | |
| 09.01. | Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C) | 330 | Business Wire | Expanded collaboration builds on Acepodia and Biocytogen's recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs
Biocytogen Pharmaceuticals (Beijing)... ► Artikel lesen | |
| 31.12.25 | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 31.12.25 | BIOCYTOGEN-B (02315): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 24.12.25 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT | 2 | HKEx | ||
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Börsengang am STAR-Markt ab und wird zum ersten globalen Arzneimittelentwickler mit "H+A"-Status | 557 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine... ► Artikel lesen | |
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 603 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing... ► Artikel lesen | |
| 10.12.25 | BIOCYTOGEN-B (02315): NEXT DAY DISCLOSURE RETURNS | 4 | HKEx |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,030 | -15,73 % | Medigene: Zurückziehung - 18.11.2025 | ||
| BIOFRONTERA | 2,620 | -1,87 % | Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition | ||
| CLINUVEL | 5,810 | 0,00 % | CLINUVEL PHARMACEUTICALS LIMITED: Chair Letter to Shareholders | ||
| EDITAS MEDICINE | 2,053 | +1,68 % | Is Editas Medicine Going to $0? | ||
| ASEP MEDICAL | 0,163 | 0,00 % | ASEP Medical Holdings Inc (2): Asep Medical appoints O'Shaughnessy as director | ||
| CELLECTAR BIOSCIENCES | 3,240 | +4,52 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,540 | -0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| CLEAN HARBORS | 238,20 | -0,25 % | Truist reiterates Clean Harbors stock rating on PFAS disposal rules | ||
| SPERO THERAPEUTICS | 2,040 | -0,73 % | Spero Therapeutics, Inc.: Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 | ||
| MESOBLAST | 1,220 | +5,17 % | Kommerzialisierung von Stammzelltherapien nimmt Fahrt auf - Mesoblast im Fokus | ||
| LIR LIFE SCIENCES | 0,271 | -6,87 % | EQS-Media: First-Mover mit erheblichem Skalierungspotenzial: LIR Life Sciences setzt Innovations-Roadmap fort | EQS-Media / 06.02.2026 / 16:20 CET/CEST
LIR Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), LIR oder das Unternehmen, freut sich bekannt zu geben, dass es mit "Neuland Laboratories Limited"... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,695 | -2,11 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - AACR 2026 PREVIEW: CSTONE TO PRESENT PRECLINICAL DATA FOR THREE PROPRIETARY PIPELINE ASSETS | ||
| PROTALIX BIOTHERAPEUTICS | 1,890 | +2,16 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio®... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 99,00 | +1,54 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin | Patent strengthens global intellectual property protection for QTORIN rapamycin, Palvella's lead product candidate from the QTORIN platform, in development for serious, rare skin diseases and vascular... ► Artikel lesen | |
| PURPLE BIOTECH | 3,890 | -1,77 % | Purple Biotech regains compliance with Nasdaq |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,120 (+2,17 %) liegt der Kurs bei 5,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.